Skip to menu Skip to content Skip to footer

2009

Conference Publication

Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study

Mollee, Peter, Jones, Mark, Stackelroth, Jenny, van Kuilenburg, Rosita, Joubert, Warren, Faoagali, Joan, Looke, David, Harper, John and Clements, Archie (2009). Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study. 51st ASH Annual Meeting, New Orleans, LA United States, 5–8 December 2009. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v114.22.1382.1382

Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study

2009

Conference Publication

WT1 expression levels at diagnosis and as a marker of minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML)

Gray, James X, McMillen, Lyle, Saal, Russell, Lane, Steven, Mollee, Peter, Bird, Robert, Gill, Devinder and Marlton, Paula (2009). WT1 expression levels at diagnosis and as a marker of minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML). 51st ASH Annual Meeting, New Orleans, LA, 5-8 December 2009. American Society of Hematology. doi: 10.1182/blood.v114.22.2639.2639

WT1 expression levels at diagnosis and as a marker of minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML)

2009

Journal Article

Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies

Mollee, Peter (2009). Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. Clinical Biochemist Reviews, 30 (3), 93-103.

Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies

2009

Journal Article

Quantitative serum free light chain assay--analytical issues

Tate, Jill, Bazeley, Sheree, Sykes, Stephen and Mollee, Peter (2009). Quantitative serum free light chain assay--analytical issues. The Clinical biochemist. Reviews, 30 (3), 131-40. doi: 10.1186/1471-2369-9-11

Quantitative serum free light chain assay--analytical issues

2009

Journal Article

Monoclonal Gammopathies – Clinical and Laboratory Issues

Tate, Jill, Mollee, Peter and Johnson, R. (2009). Monoclonal Gammopathies – Clinical and Laboratory Issues. Clinical Biochemist Reviews, 30 (3), 89-91.

Monoclonal Gammopathies – Clinical and Laboratory Issues

2009

Journal Article

Borderline High Serum Free Light Chain κ/λ Ratios Are Seen Not Only in Dialysis Patients but Also in Non–Dialysis-Dependent Renal Impairment and Inflammatory States

Marshall, George, Tate, Jill and Mollee, P. (2009). Borderline High Serum Free Light Chain κ/λ Ratios Are Seen Not Only in Dialysis Patients but Also in Non–Dialysis-Dependent Renal Impairment and Inflammatory States. American Journal of Clinical Pathology, 132 (2), 309-309. doi: 10.1309/AJCP8VOT5TVLAQBQ

Borderline High Serum Free Light Chain κ/λ Ratios Are Seen Not Only in Dialysis Patients but Also in Non–Dialysis-Dependent Renal Impairment and Inflammatory States

2009

Journal Article

Quantitative serum free light chain assay: Analytical issues

Tate, Jill, Bazeley, Sheree, Sykes, Stephen and Mollee, Peter (2009). Quantitative serum free light chain assay: Analytical issues. Clinical Biochemist Reviews, 30 (3), 131-140.

Quantitative serum free light chain assay: Analytical issues

2009

Journal Article

Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation

Hall, S. L., Tate, J., Gill, D. and Mollee, P. (2009). Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation. Clinical Biochemist Reviews, 30 (3), 113-118.

Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation

2009

Conference Publication

Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study

Mollee, Peter, Jones, Mark, Stackelroth, Jenny, van Kuilenburg, Rosita, Joubert, Warren, Faoagali, Joan, Looke, David, Harper, John and Clements, Archie (2009). Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study. 51st ASH Annual Meeting and Exposition, New Orleans, LA, U.S.A., 5-8 December 2009. Washington, DC, U.S.A.: American Society of Hematology.

Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study

2009

Conference Publication

WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaernia (AML)

Gray, J. X., McMillen, L., Saal, R., Lane, S., Mollee, P., Bird, R., Gill, D. and Marlton, P. (2009). WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaernia (AML). 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, United States, 5-8 December 2009. Washington, DC, United States: American Society of Hematology.

WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaernia (AML)

2009

Conference Publication

Sequential treatment with Rituximab and CHOP chemotherapy in B-Cell PTLD - moving forward to a first standard of care: Results from a prospective international multicenter trial

Trappe, Ralf, Choquet, Sylvain, Oertel, Stephan H.K., Leblond, Veronique, Dierickx, Daan, Mollee, Peter, Sender, Monica, Ekman, Tor, Zaucha, Jan Maciej, Reinke, Petra, Neuhaus, Ruth, Lehmkuhl, Hans, Dreyling, Martin H., Duhrsen, Ulrich, Salles, Gilles, Morschhauser, Franck, Jaccard, Arnaud, Lamy, Thierry, Anagnostopoulos, Ioannis, Raphael, Martine, Dorken, Bernd and Riess, Hanno (2009). Sequential treatment with Rituximab and CHOP chemotherapy in B-Cell PTLD - moving forward to a first standard of care: Results from a prospective international multicenter trial. 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, United States, 5 - 8 December 2009. Washington, DC, United States: American Society of Hematology.

Sequential treatment with Rituximab and CHOP chemotherapy in B-Cell PTLD - moving forward to a first standard of care: Results from a prospective international multicenter trial

2008

Conference Publication

Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro

Gill, Devinder, Burgess, Melinda, Knop, Louise, Mollee, Peter and McMillan, Nigel (2008). Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro. 50th ASH Annual Meeting, San Francisco, CA United States, 6-9 December 2008. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v112.11.3157.3157

Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro

2008

Conference Publication

Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) population

Keane, Colm G., Mollee, Peter, Marlton, Paula and Gill, Devinder (2008). Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) population. 50th ASH Annual Meeting, San Francisco, CA United States, 6-9 December 2008. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v112.11.4014.4014

Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) population

2008

Journal Article

A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation

Hourigan, Matthew J., Doecke, James, Mollee, Peter N., Gill, Devinder S., Norris, Debra, Johnson, David W. and Gandhi, Maher K. (2008). A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation. British Journal of Haematology, 141 (6), 904-907. doi: 10.1111/j.1365-2141.2008.07149.x

A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation

2008

Journal Article

Prolonged haematological toxicity from the hyper-CVAD regimen: Manifestations, frequency, and natural history in a cohort of 125 consecutive patients

Gill, Saar, Lane, Steven, Crawford, Julie, Cull, Gavin, Joske, David, Joske, David, Marlton, Paula, Mollee, Peter, Prince, Miles and Seymour, John (2008). Prolonged haematological toxicity from the hyper-CVAD regimen: Manifestations, frequency, and natural history in a cohort of 125 consecutive patients. Annals of Hematology, 87 (9), 727-734. doi: 10.1007/s00277-008-0488-6

Prolonged haematological toxicity from the hyper-CVAD regimen: Manifestations, frequency, and natural history in a cohort of 125 consecutive patients

2008

Journal Article

A 1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor accute myeloid leukemia and predicts subsequent morphologic relapse

Lane, Steven, Saal, Russell, Mollee, Peter, Jones, Mark, Grigg, Andrew, Taylor, Kerry, Seymour, John, Kennedy, Glen, Williams, Bronwyn, Grimmett, Karen, Griffiths, Vanessa, Gill, Devinder, Hourigan, Matthew and Marlton, Paula (2008). A 1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor accute myeloid leukemia and predicts subsequent morphologic relapse. Leukemia & Lymphoma, 49 (3), 517-523. doi: 10.1080/10428190701817266

A 1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor accute myeloid leukemia and predicts subsequent morphologic relapse

2008

Conference Publication

Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro

Gill, Devinder, Burgess, Melinda, Knop, Louise, Mollee, Peter and McMillan, Nigel (2008). Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro. 50th Annual Meeting of the American- Society-of-Hematology, San Francisco, CA, United States, 6 - 9 December 2008. Washington, DC, United States: American Society of Hematology.

Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro

2008

Conference Publication

Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases - Analytical and clinical correlations

Tate, J.R., Bazeley, S., Sykes, S. and Mollee, P. (2008). Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases - Analytical and clinical correlations. 60th Annual Meeting of the American Association for Clinical Chemistry, Washington, DC, United States, 27-31 July 2008. Washington, DC, United States: American Association for Clinical Chemistry.

Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases - Analytical and clinical correlations

2007

Conference Publication

Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients

Mollee, Peter, Hourigan, Matthew, Johnson, David, Jones, Mark, Isbel, Nikki, Hawley, Carmel, Marlton, Paula, Gandhi, Maher, Campbell, Scott and Gill, Devinder (2007). Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients. 49th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA USA, 8-11 December 2007. Washington, DC USA: American Society of Hematology.

Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients

2007

Conference Publication

JAK2 V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET)

Weston, Helen, Bird, Robert, Griffiths, Vanessa, Jones, Mark, Grimmett, Karen, Saal, Russell, Mills, Anthony K., Gill, Devinder, Marlton, Paula and Mollee, Peter (2007). JAK2 V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET). 49th ASH Annual Meeting, Atlanta, GA United States, 8-11 December 2007. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v110.11.2551.2551

JAK2 V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET)